## A comparison of a structured homebased rehabilitation programme with conventional supervised pulmonary rehabilitation: A randomised noninferiority trial

Horton, E., Mitchell, K. E., Johnson-Warrington, V., Apps, L. D., Sewell, L., Morgan, M., Taylor, R. S. & Singh, S. Author post-print (accepted) deposited by Coventry University's Repository

## Original citation & hyperlink:

Horton, E, Mitchell, KE, Johnson-Warrington, V, Apps, LD, Sewell, L, Morgan, M, Taylor, RS & Singh, S 2017, 'A comparison of a structured home-based rehabilitation programme with conventional supervised pulmonary rehabilitation: A randomised non-inferiority trial' Thorax, vol 73, no. 1, pp. 29-36. https://dx.doi.org/10.1136/thoraxjnl-2016-208506

DOI 10.1136/thoraxjnl-2016-208506 ISSN 0040-6376 ESSN 1468-3296 Publisher: BMJ

Copyright © and Moral Rights are retained by the author(s) and/ or other copyright owners. A copy can be downloaded for personal non-commercial research or study, without prior permission or charge. This item cannot be reproduced or quoted extensively from without first obtaining permission in writing from the copyright holder(s). The content must not be changed in any way or sold commercially in any format or medium without the formal permission of the copyright holders.

This document is the author's post-print version, incorporating any revisions agreed during the peer-review process. Some differences between the published version and this version may remain and you are advised to consult the published version if you wish to cite from it.

# A comparison of a structured home-based rehabilitation programme with conventional supervised pulmonary rehabilitation: A randomised non-inferiority trial

## Authors:

Elizabeth J Horton<sup>1</sup>, Katy E Mitchell<sup>2</sup>, Vicki Johnson-Warrington<sup>2</sup>, Lindsay D Apps<sup>2</sup>, Louise

Sewell<sup>2</sup>, Mike Morgan<sup>2</sup>, Rod S Taylor<sup>3</sup>, Sally J Singh<sup>2,4</sup>

## Address for authors:

<sup>1</sup>Faculty of Health and Life Sciences, Coventry University, Priory Street, Coventry, CV1 5FB,

UK

<sup>2</sup>Centre for Exercise and Rehabilitation Science, University Hospitals Leicester NHS Trust,

Leicester, LE3 9QP, UK

<sup>3</sup>University of Exeter Medical School, St Luke's Campus, Exeter, EX1 2LU, UK

<sup>4</sup>National Centre for Sport and Exercise Medicine, Loughborough University, Leicester, LE11

3TU, UK

## **Corresponding Author**:

Elizabeth Horton Faculty of Health and Life Sciences Coventry University Priory Street Coventry CV1 5FB

Tel: 0247 7658915

<u>e.horton@coventry.ac.uk</u>

Key words:

Pulmonary rehabilitation Exercise Dyspnoea Word Count: excluding tables, figure/table titles and legends 3,373 Contribution to paper

Study Design – EH, LS, MM &SS

Data collection and Management – EH, KM, VJW, LA, LS

Data Analysis – EH & RT

Writing and editing of manuscript - All

Support GSK provided an unrestricted monetary grant to part fund the this study

Running head Home-based pulmonary rehabilitation programme for COPD

**Twitter feed:** A standardised home-based PR programme demonstrates benefits in dyspnoea and exercise performance

#### **Key Message**

#### What is the key question?

Can a structured home-based unsupervised pulmonary rehabilitation programme of activity,

coping and education for COPD be considered non-inferior to centre-based pulmonary

rehabilitation?

#### What is the bottom line?

The home-based programme achieved improvements in dyspnoea and exercise endurance

capacity to a similar level to conventional supervised PR. However, non-inferiority remains

inconclusive.

## Why read on?

This study demonstrates that a structured home-based pulmonary rehabilitation programme can provide some health improvements and may provide an alternative for those unable to attend centre based pulmonary rehabilitation.

#### ABSTRACT

**Background:** Standardised home-based pulmonary rehabilitation (PR) programmes offer an alternative model to centre-based supervised PR for which uptake is currently poor. We determined if a structured home-based unsupervised PR programme was non-inferior to supervised centre-based PR for participants with COPD.

**Methods**: 287 participants with COPD who were referred to PR (187 male, mean (SD) age 68 (8.86) years, FEV<sub>1</sub>% predicted 48.34 (17.92)) were recruited. They were randomised to either centre-based PR or a structured unsupervised home-based PR programme including a hospital visit with a healthcare professional trained in motivational interviewing, a self-management manual and two telephone calls. 58 (20%) withdrew from the centre based group and 51(18%) from the home group. The primary outcome was dyspnoea domain in the chronic respiratory disease questionnaire (CRQ-SR) at seven weeks. Measures were taken blinded. We undertook a modified intention to treat (mITT) complete case analysis, comparing groups according to original random allocation and with complete data at follow up. The non-inferiority margin was 0.5 units

**Results**: There was evidence of significant gains in CRQ-dyspnoea at seven weeks in both home and centre-based groups. There was inconclusive evidence that home-based PR was non-inferior to PR in dyspnoea (mean group difference, mITT: -0.24, 95% CI -0.61 to 0.12, p0.18), favouring the centre group at seven weeks.

**Conclusions**: The standardised home-based programme provides benefits in dyspnoea. Further evidence is needed to definitively determine if the health benefits of the standardised home-based programme are non-inferior or equivalent to supervised centrebased rehabilitation. **Trial registration:** ISRCTN81189044

Word count: 247 words

#### INTRODUCTION

Pulmonary rehabilitation (PR) is a highly effective intervention for individuals with chronic obstructive pulmonary disease (COPD) and other chronic respiratory diseases. International guidance suggests that the programme should be a package of supervised exercise and education over a minimum of six weeks.[1] Over the years the format of rehabilitation has altered very little. The content and formats of rehabilitation have been extensively investigated but alternative modes of delivery have been poorly reported.[2] Maltais [3] reported that home-based exercise training was equivalent to a centre-based programme but this programme was supplemented by an initial 4-week centre-based education programme. Although the data suggested that home training was possible (with the provision of an exercise bike) the programme did require regular attendance at a rehabilitation centre. There have been small scale studies that have looked at alternative forms of home-based rehabilitation but the design and sample size has not been adequate for a firm recommendation to be made. [4, 5] A more recent trial [6] demonstrated that a weekly monitored home-programme was equivalent to centre-based PR, however included a home visit by a physiotherapist and weekly telephone calls including personalised educational content. There is a lack of evidence for a, standardised and unsupervised rehabilitation programme that have no home visits by a physiotherapist or intensive monitoring. A current research priorities document acknowledged this slow progress and proposed that alternative modes of delivery be investigated.[7]

Developing and testing an acceptable alternative to centre-based supervised rehabilitation would seem reasonable to increase the scope and choice of intervention. Furthermore it

may be a viable alternative for a number of people who are either unwilling or unable to attend a supervised programme.[8] Many centres face challenges in meeting the demand and an alternative approach may help alleviate capacity issues. [9]

We have recently reported the effectiveness of a supported, but unsupervised home-based PR programme that was facilitated by a standardised manual that participants worked through (SPACE for COPD – a Self-management Programme of Activity Coping and Education; [10]). Compared to control subjects we observed important changes in health related quality of life (self-report dyspnoea domain on the Chronic Respiratory Questionnaire (CRQ-SR) mean change at six weeks 0.71 units, 95% Cl 0.45 to 1.00, p=0.049) and exercise capacity (Endurance Shuttle Walk Test (ESWT) mean change at six weeks 209.7 sec, 95% Cl 122.3 to 297.1, p=0.006). These are two important outcomes that define the success of a conventional rehabilitation programme. We were therefore interested to examine whether the use of this home-based programme would provoke similar improvements to those in supervised PR. The use of a home-based approach supported by a standardised manual already exists for cardiac rehabilitation.[11] It would seem that a comparison of structure and standardised home-based rehabilitation with centre-based pulmonary rehabilitation would be a valuable addition.

Therefore, the aim of this study was to compare the home-based programme supported by the SPACE for COPD manual with conventional supervised centre-based PR. We hypothesised that this novel approach to deliver a home-based programme would not result in an inferior outcome at seven weeks compared to supervised rehabilitation at seven weeks. The primary outcome of the study was a change in dyspnoea at seven weeks,

measured by the CRQ-SR. [12] Secondary aims were to explore the impact of the home programme in comparison to other measures of health related quality of life, exercise capacity and psychological status at seven weeks and six months.

#### METHODS

We conducted an assessor blinded, non-inferiority, randomised controlled trial comparing centre-based PR with a home-based programme supported with the SPACE for COPD manual with the primary end point at seven weeks, and follow up at six months. The study took place between November 2007 and July 2012. All participants gave written informed consent, and ethical approval for the study was granted by Leicestershire Northamptonshire and Rutland Regional Ethics Committee, reference 07/Q2501/6.

#### Subjects

Participants with COPD, and MRC score of 2-5 were recruited from those referred to PR at Glenfield hospital and Leicester General hospital, UK. Exclusion criteria included those that would normally prohibit access to PR such as lower limb disability and other unstable comorbid conditions. Participants that had completed PR in the previous 12 months were also excluded. Participants were required to have a proficient level of English.

#### Study design

The study was designed to show non inferiority of a home-based rehabilitation programme as compared to a standard centre-based programme. The primary outcome was the selfreport dyspnoea component of the CRQ-SR at seven weeks, this was chosen because of its clinical relevance and it's potential to show differences between the two groups. Secondary endpoints included measures of exercise tolerance, self-efficacy, anxiety and depression.

#### **Recruitment and randomisation**

Participants were recruited at their referral appointment to PR and all baseline measures were taken as part of the usual referral process. Participants interested in the study were subsequently contacted and a consent appointment arranged. Randomisation was completed, using a random permuted blocks method with a 1:1 allocation ratio and sealed opaque envelopes. Randomisation was completed by a researcher not involved in the study.

#### Intervention

Participants randomised to the PR group completed the usual centre-based programme of twice weekly hospital based supervised exercise and education programme over seven weeks, as previously described.[13] Participants randomised to the home-based group had an initial introductory session at the hospital led by a healthcare professional trained in Motivational Interviewing, instructing them how to use the manual to facilitate their home exercise programme.[14] Participants in this group received two standardised telephone calls during the seven weeks to assess their progress, support and motivate the participant to continue and to answer any questions. It was anticipated that participants would take seven weeks to progress through the SPACE for COPD manual. However, the manual was theirs to keep and could support lifelong lifestyle changes. Details of the SPACE for COPD manual have been previously been reported.[10, 14] Both interventions were progressive and based on a daily walking programme with speed and initial duration determined by their performance in the incremental shuttle walk test (ISWT) and ESWT at their baseline

assessment. Participants were advised to increase the duration of their walk each day. Resistance exercises covered the major muscle groups and were completed three times a week. A detailed description of both interventions is available in the online supplement.

#### **Outcome measures**

Outcome measures were completed at baseline, seven weeks, and six months post intervention to understand the durability of the intervention. Outcome measures taken at seven weeks and six months were conducted by a member of staff blinded to the allocation of the participants. Participants were instructed not to identify group allocation. If assessment appointments were missed, we attempted to reschedule on two further occasions. If they did not attend, these participants were then withdrawn from the study. All participants completed the outcome measures relating to health status and exercise performance (unless stated).

The primary outcome for this paper is the CRQ-SR at seven weeks, although we have included six month findings. Our ISRCTN (International Standard Randomised Controlled Trial Number) previously stated that our primary outcome was the dyspnoea domain of the CRQ-SR,[12] at seven weeks and six months. This was inaccurate, it is unusual to have a primary outcome at two time points. A higher score for the CRQ-SR indicates less impairment to quality of life. Secondary outcomes were the fatigue, emotional functioning and mastery domains of the CRQ-SR, and anxiety and depression as measured by the Hospital Anxiety and Depression scale (HADS; [15]), Self-efficacy by the Pulmonary Rehabilitation Adapted Index of Self-Efficacy (PRAISE; [16]) and the ISWT and ESWT [17, 18].

#### Sample size

For the primary outcome measure, a difference of 0.5 has been recognised as the minimum clinically important difference (MCID[19]), with a common SD of 1.1. [13] Using these values in the sample size calculation to assess non inferiority, with an alpha level of 0.025, and a 2 sided test with 90% power, the required sample size was 314. Based on an attrition rate of 15% typically seen in the hospital rehabilitation group, 320 participants per group were targeted for recruitment. As it took longer to recruit and the drop-out rate experienced was higher than anticipated we reduced the power to 80%. This resulted in a lower participant sample size of 177 required. We continued to recruit until sample size was achieved.

#### **Data Analysis**

We analysed and reported primary and secondary outcomes following CONSORT guidelines for non-inferiority and equivalence trials.[20] In our primary analysis we compared primary and secondary outcomes between groups at post-randomisation using linear regression models adjusted for baseline outcomes. We undertook modified intention-to-treat (mITT) complete case analysis and per protocol (PP) analysis, given that security of inference depends on both PP and mITT analysis demonstrating non-inferiority. [20]Our mITT population comprises all participants according to and included in random allocation and with complete data. We defined the PP population as participants meeting the mITT definition and attending the final outcome assessment.

We accepted non-inferiority of home-based to centre-based PR (in a 0.025 level test) if the lower boundary of the two-sided 95% CI (equivalent to the upper bound of one-sided 97.5%

CI) was within the non-inferiority margin of the MCID of 0.5 units for each of the 4 CRQ domains[19], 1.5 units for the HADS[15], 48m for the ISWT[21] and 186 seconds for the ESWT[22]. We checked for non-inferiority of the primary and secondary outcome at the six month point using the same approach.

We undertook three groups of secondary analysis. First we compared groups at follow up, at six months as for primary analysis and checked for non-inferiority using the same approach as described above. Second, we assessed the likely effect of missing data using multiple imputation models. We did imputation by treatment group using chained equations to create 10 complete datasets under the assumption that data were missing at random. 22 imputation models included covariates as defined for the primary model. After analysis, we combined the effect estimates from the imputed datasets using Rubin's rule [23]. Analysis were undertaken using STATA 14.1.

## RESULTS

The flow of participants through the trial is summarised in figure 1. 287 participants were recruited and randomised to the study, 142 to centre-based and 145 to home-based PR (table 1). There were patients with missing data from the baseline appointment. Missing data from questionnaires was due to non-completion of the form.

#### Insert Figure 1 here

Figure 1. Consolidation Standards of Reporting Trials flow diagram of participation. MRC: Medical Research Council; COPD: Chronic Obstructive Pulmonary Disease; PR: Pulmonary Rehabilitation; Table 1. Baseline Characteristics and demographics

	Home-based n=145 (unless otherwise stated)	Centre-based n=142(unless otherwise stated)	
Age years	68 (9)	67 (8)	
Male:Female n (%)	93 (64):52 (36)	94 (66):48(34)	
BMI m/kg <sup>2</sup>	27 (6)	28 (6)	
FEV <sub>1</sub> litres	1.26 (0.51)	1.26 (0.60)	
FEV <sub>1</sub> , per cent predicted	47.89 (18.67)	48.79 (17.19)	
FVC litres,	2.73 (0.84)	2.67 (0.90)	
MRC, n(%)			
2	28 (19)	20 (14)	
3	52 (36)	57 (40)	
4	47 (33)	39 (28)	
5	18 (12)	26 (18)	
Per cent SpO <sub>2</sub> at rest	94.54 (2.32)	93.91 (3.66)	
Smoking status, n (%)			
Current smoker	45 (31)	28 (20)	
Never smoked	8 (6)	5 (3)	
Ex-smoker	92 (63)	109 (77)	
Pack years, n	47 (36), 136	45 (26), 135	
Supplementary oxygen n (%)	9 (6)	15 (11)	
CRQ-SR, n			
Dyspnoea	2.58 (0.93), 137	2.42 (0.91), 129	
Fatigue	3.42 (1.19), 137	3.36 (1.20), 129	
Emotion	4.41 (1.24), 137	4.37 (1.24), 129	

Mastery	4.50 (1.40), 137	4.36 (1.30), 129
HADS		
Anxiety n (%)		
0-7	83 (57)	68 (48)
8-10	32 (22)	46 (32)
11-14	22 (15)	21 (15)
15-21	9 (6)	7 (5)
Depression n (%)		
0-7	104 (71)	98 (69)
8-10	23 (16)	27 (19)
11-14	16 (11)	13 (9)
15-21	3 (2)	4 (3)
PRAISE, n	47.24 (8.09), 130	44.81 (7.00), 122
ISWT meters, n	260 (148)	269 (150), 139
ESWT seconds, n	231 (231), 144	189 (96), 139

Data are presented as mean (± SD) or number (%). BMI: body mass index; FEV<sub>1</sub>: forced expiratory volume in 1 s; FVC: forced vital capacity; MRC: Medical Research Council; SpO<sub>2</sub>: oxygen saturation; CRQ-SR: Chronic Respiratory Questionnaire – Self Report; HADS: Hospital Anxiety and Depression Scale; PRAISE: Pulmonary Rehabilitation Adapted Index of Self-Efficacy; ISWT: Incremental Shuttle Walk Test; ESWT: Endurance Shuttle Walk Test. A total of 109 participants withdrew from the study. 58 people (41%) did not complete the seven week assessment in the centre-based group and 51 people (35%) did not complete the seven week assessment in the home-based group. Reasons for dropout are listed in figure 1. There was no evidence of substantive differences in baseline characteristics of those that did or did not complete the seven week assessment (see online supplement table S1).

#### **Primary outcome**

At seven weeks we observed statistically significant improvements in both groups for the dyspnoea component of the CRQ-SR. The between-group differences were small (mITT: - 0.24, 95% CI -0.61 to 0.12, p=0.18; PP: -0.38, 95% CI -0.79 to 0.02, p=0.06; table 2) and not statistically significant. The lower confidence interval exceeds the MCID of 0.5 units, therefore, there remains a degree of uncertainty as to the effectiveness of the home-based intervention on dyspnoea (figure 2). The percentage of participants in each group meeting the MCID threshold of 0.5 for the dyspnoea domain of the CRQ-SR was not significantly different between the two groups (p=0.669), 58.9% and 53.9% for the centre and home-based programmes respectively (table 3).

	Home-based Mean (SD) N	Centre- based Mean (SD) N	Between group difference (home- centre)* Mean difference (95% Cl) p value	Inference regarding non-inferiority
CRQ-SR				
dyspnoea	3.15 (1.26)	3.38 (1.20)	-0.24 (-0.61 to 0.12) 0.18	Inconclusive
mITT	79	83	-0.38 (-0.79 to 0.02) 0.06	Inconclusive

# Table 2. Between group difference in primary and secondary outcomes at seven weekspost-randomisation follow up – complete case analysis

РР	3.01 (1.22) 62	3.38 (1.22) 70		
CRQ-SR fatigue mITT PP	3.71 (1.21) 82 3.78 (1.22) 65	4.12 (1.49) 83 4.12 (1.56) 70	-0.40 (-0.73 to 0.07) 0.02 -0.36 (-0.73 to 0.02) 0.06	Inconclusive Inconclusive
CRQ-SR emotion mITT PP	4.55 (1.20) 82 4.57 (1.23) 65	4.91 (1.06) 81 4.83 (1.06) 68	-0.45 (-0.75 to 0.16) 0.01 -0.44 (-0.78 to -0.11) 0.01	Inconclusive Inconclusive
CRQ-SR mastery mITT PP	4.78 (1.30) 82 4.78 (1.28) 65	4.97 (1.21) 82 4.83 (1.06) 68	-0.36 (-0.66 to 0.07) 0.02 -0.31 (-0.64 to 0.01) 0.06	Inconclusive Inconclusive
HADS anxiety mITT PP	7.15 (4.05) 81 6.83 (3.93) 64	6.74 (3.76) 86 6.92 (3.53) 71	0.73 (0.17 to 1.63) 0.11 0.57 (-0.40 to 1.54) 0.25	Inconclusive Inconclusive
HADS depression mITT PP	6.07 (3.68) 82 5.91 (3.67) 64	5.49 (3.16) 86 5.45 (3.20) 71	0.84 (0.04 to 1.63) 0.04 0.94 (0.07 to 1.81) 0.04	Inconclusive Inconclusive
PRAISE mITT PP	44.72 (8.50) 81 45.28 (8.62) 65	47.08 (7.72) 84 47.57 (7.09) 69	-2.58 (-4.87 to -0.30) 0.03 -2.44 (-4.90 to 0.02) 0.05	No non-inferiority margin No non-inferiority margin
ISWT distance (m) mITT PP	281.18 (147.92) 85 288.18 (148.76) 66	309.53 (156.43) 85 311.27 (165.81) 71	-23.56 (-45.30 to -1.81) 0.03 -19.87 (-44.39 to 4.65) 0.11	non-inferior non-inferior
ESWT time (sec) mITT PP	442.00 (391.34) 85 468.53 (410.27) 66	545.98 (408.58) 82 541.50 (417.30) 70	-141.43 (-252.23 to - 30.63) 0.01 -128.10 (-254.31 to - 1.89) 0.05	Inconclusive Inconclusive

mITT: intention to treat – all participants according to random allocation with outcome data; PP: Per protocol – participants according to random allocation with outcome data and attending final outcome assessment; N: number participants; CRQ-SR: Chronic Respiratory Questionnaire Self Report; HADS: Hospital Anxiety and Depression Scale; ISWT: Incremental shuttle walk test; ESWT: Endurance Shuttle Walk Test

\*Adjusted for baseline score

Table 3. Participants meeting the MCID (0.5 units) for the CRQ-SR dyspnoea domain in

	Change <0.5	Change ≥ 0.5	Range (-7 to 7)	р
	%	%		
Centre-based	41.10	58.90	-1.60 to 3.2	0.669
Home-based	46.05	53.95	-3.0 to 4.6	

Centre and Home-based groups. Complete case-analysis

#### Insert Figure 2 here

Figure 2. Between group change in Chronic Respiratory Questionnaire self-report (CRQ-SR) dyspnoea and non-inferiority margin.

Data are mean and 95% CI. The dotted line represents the non-inferiority margin.

### Secondary outcomes

Within-group changes in the CRQ-SR fatigue, emotion and mastery, from baseline to seven weeks showed that there was a significant improvement in these domains in the centre-based group only. 95% CI imply that the non-inferiority of the home-based programme remains inconclusive (table 2 and online supplement).

There were no significant differences between the two groups for anxiety (-0.97, 95%CI -1.98 to 0.04) or depression (-0.79, 95% CI -1.63 to 0.04) (both p=0.06) at seven weeks. However,

the non-inferiority margin (1.5 units) is breached by the 95% CI for both domains (table 2 and online supplement). Therefore the non-inferiority of home-based PR cannot be confirmed.

No MCID is established for self-efficacy and therefore inference can't be made. However, between group difference was significantly different in favour of the centre-based group.

Both groups improved their performance on the ISWT (p<0.001 for PR and p=0.015 for the home based group). The between group differences in ISWT distance was non-inferior to PR (mITT: -23.56, 95% CI -45.30 to -1.81, p0.03; PP: -19.87, 95% CI -44.39 to 4.65, p0.11; table 2 and online supplement).

Important gains were made in ESWT performance for both groups (centre-based 353 (95% CI 270 to 437) seconds, p=0.001; home-based 212 (95%CI 139 to 284) seconds, p<0.001), with mean change exceeding the MCID in both groups. There was a significant between group differences in ESWT time (mITT: -141.43, 95% CI -253.25 to -30.63, p0.01; PP: -128.10, 95% CI -254.31 to -1.89, p0.05; table 2) in favour of centre-based rehabilitation. The non-inferiority margin (i.e. the MCID 186 seconds) was breached by the lower CI and therefore the non-inferiority of home PR is inconclusive.

#### Six month follow up

At six months there was no significant difference in any of the recorded variables (table 4). Gains in ESWT performance were largely maintained at six months in both groups (table 4). This was not observed for the ISWT where both groups declined to baseline performance levels. Home-based was non-inferior to centre-based in the ISWT at six months. The gain

observed in the dyspnoea component of the CRQ declined in both groups, but remained above

the MCID of 0.5 in the centre-based PR group.

	Home- based Mean (SD) N	Centre- based Mean (SD) N	Between group difference (home- centre)* Mean difference (95% Cl) P-value	Inference regarding non-inferiority
CRQ-SR dyspnoea mITT PP	2.80 (1.17) 66 2.77 (1.14) 64	3.08 (1.26) 70 3.08 (1.27) 68	-0.36 (-0.75 to 0.03) 0.07 -0.39 (-0.79 to 0.002) 0.05	Inconclusive Inconclusive
CRQ-SR fatigue mITT PP	3.53 (1.40) 67 3.52 (1.38) 65	3.60 (1.31) 71 3.58 (1.31) 69	-0.18 (-0.58 to 0.22) 0.38 -0.18 (-0.58 to 0.23) 0.39	Inconclusive Inconclusive
CRQ-SR emotion mITT PP	4.34 (1.34) 67 4.35 (1.34) 65	4.49 (1.24) 71 4.48 (1.24) 69	-0.29 (-0.64 to 0.05) 0.09 -0.31 (-0.66 to 0.04) 0.08	Inconclusive Inconclusive
CRQ-SR mastery mITT PP	4.55 (1.49) 67 4.55 (1.45) 65	4.61 (1.43) 71 4.60 (1.44) 69	-0.30 (-0.71 to 0.10) 0.14 -0.30 (-0.71 to 0.11) 0.15	Inconclusive Inconclusive
HADS anxiety mITT PP	7.31 (4.29) 68 7.32 (4.27) 66	7.96 (4.18) 73 8.02 (4.20) 71	0.13 (-0.93 to 1.19) 0.81 0.21 (-0.87 to 1.29) 0.70	Non-inferior Non-inferior
HADS depression mITT PP	6.26 (3.57) 68 6.30 (3.55) 66	6.52 (3.59) 73 6.54 (3.58) 71	0.07 (-0.92 to 1.07) 0.88 0.14 (-0.85 to 1.14) 0.78	Inconclusive Inconclusive
PRAISE mITT PP	43.21 (8.87) 68 43.20 (8.81) 66	44.11 (8.79) 72 44.16 (8.87) 70	-1.15 (-3.97 to 1.67) 0.42 -1.05 (-3.93 to 1.83) 0.47	No non-inferiority margin No non-inferiority margin

Table 4. Between group difference in primary and secondary outcomes at six months postrandomisation follow up – complete case analysis

ISWT				
distance (m)	248.14	270.00	-5.46 (-32.98 to 22.05)	Non-inferior
mITT	(151.86) 59	(150.94) 66	0.70	Non-inferior
PP	247.24	271.25	-5.87 (-33.99 to 22.25)	
	(153.03) 58	(153.05) 64	0.68	
ESWT time				
(sec)	408.27	444.70	-67.83 (-207.69 to	Inconclusive
mITT	(420.09) 59	(414.89) 67	72.04) 0.34	Inconclusive
РР	407.03	445.02	-69.58 (-212.23 to	
	(423.65) 58	(417.44) 65	73.07) 0.34	

mITT: intention to treat – all participants according to random allocation with outcome data; PP: Per protocol – participants according to random allocation with outcome data and attending final outcome assessment; N: number participants; CRQ-SR: Chronic Respiratory Questionnaire Self Report; HADS: Hospital Anxiety and Depression Scale; ISWT: Incremental shuttle walk test; ESWT: Endurance Shuttle Walk Test \*Adjusted for baseline score

Results from the secondary analysis on the imputed data showed comparable finding to the complete case analysis (see supplementary table S2 for seven week data and supplementary table S3 for six month data). Within group differences are shown in table S3 of the supplementary material.

#### **Adverse Events**

During the seven week intervention phase of the study 23 adverse events occurred, 9 in the centre-based group and 14 in the home based home-based group. Two participants in the home based group and one in the centre based group died. Seven in the home based group and three in the centre based group were admitted to hospital for an exacerbation of their COPD. No serious adverse events were perceived as being related to the study intervention (See Table S5 in the online supplement). There was no significant difference between groups for events reported.

#### DISCUSSION

The hypothesis that the structure home-based unsupervised PR programme would improve self-reported dyspnoea to a similar degree to conventional centre-based PR remains inconclusive. This in line with the CONSORT recommendations [20] for reporting non inferiority trials, as the 95% CI of the difference in change between the home-based and centre-based PR groups breached the MCID of 0.5 units. However, no statistically significant difference was detected at seven weeks between home-based and centre-based PR groups for the primary outcome of dyspnoea. Interestingly, the proportion of participants achieving the MCID was also similar in each group.

There have been several home-based PR programmes reported that have deployed similar outcome measures to the current study.[3, 24] A key difference in this study is that it is a shorter intervention than many others, some which have extended to 2 years of supervision and/or support.[25] The duration of the supported phase of the intervention was comparable to the recommended length of a rehabilitation programme[26] and uniquely offered less direct or indeed indirect supervision. More recently digital versions of rehabilitation have been tested with encouraging results for those completing the programme.[27] This study is important as it demonstrates benefits acquired in a short time period similar to the outpatient model of PR. Many previous studies, although categorised as home-based actually provide more supervision and professional contact than a conventional 6-8 week course of PR.[24-26, 28] It is acknowledged that numerically the impact is probably not as great as PR for some of the outcomes and the issue of supervision could be the key factor for the differences seen. The Holland et al. study [6] demonstrated equivalence of a home based PR

with an eight week centre-based PR programme, with very similar costs. Interestingly their improvement in the six minute walk test distance was below what you might expect in a centre-based PR programme (with-group differences mITT: 10.82m, 95% CI -4.52 to 26.16).

The mean improvement in the ESWT in our study was above the MCID for both groups at seven weeks, although numerically greater in the PR group, this difference was not statistically significant. The changes following conventional centre-based PR were not as great as anticipated in the ISWT. The Mean (95% CI) change for the ISWT was 42m (24 to 59m) which falls just below the MCID of 48m for this measure. Previous studies from our centre demonstrated that the mean change for the ISWT after PR met the MCID.[10, 13, 29-31] These studies have recruited participants with, on average, lower baseline FEV<sub>1</sub>, larger numbers of participants in MRC 4 and 5 and lower mean ISWT scores. This highlights that the current study has potentially recruited a more select sub group of participants from our PR population at this centre. It is therefore possible that the effect size of outcomes may be smaller in those with milder disease. The ISWT changes in the home based group were lower than centrebased PR, although not significantly different. Participants were introduced to the study during their initial appointment and they may have seen the unsupervised home programme as the desired or 'easier option' and if subsequently randomised to PR may not have fully engaged in the programme (and therefore not complete their home exercise at a high enough intensity or frequency to elicit change in maximal exercise capacity).

Although preference to preferred intervention was not recorded in all participants, the majority of participants questioned would have chosen the home programme. It is therefore possible that this may have influenced their commitment to the programme. These numbers

were small so analysis was not completed on this data. In future it would be of interest to determine how much preference influences the outcome of the intervention. Interestingly 55% of those eligible to take part in the trial accepted the trial, despite the initial referral and expectation being for supervised rehabilitation, suggesting that in principle, the home based intervention seemed acceptable to a number of participants that had been expecting a formal course of rehabilitation.

Overall, the findings of the home based PR programme suggest that it confers some short term improvements in dyspnoea and exercise performance although not to the same degree as supervised PR. It is not possible to rule out non-inferiority as the CI exceeds the noninferiority margin.

#### Limitations

The population recruited had a subtly different profile to those generally seen in PR programmes. The reasons for this are probably multi-factorial. Participants recruited were generally less disabled by their COPD as there was a greater proportion of MRC grades 2 and 3 compared to other studies.[24-26, 28] It is likely that home programmes would allow for a more stratified approach to rehabilitation, with home programmes targeted towards those who are generally less disabled. It is also acknowledged that adherence to the programmes was not directly monitored, and that the volume of exercise was not evaluated in the home-based group. However, this was a pragmatic trial and therefore was intentional but may have impacted on the outcomes obtained.

The dropout rate for this study was higher than anticipated and may have led to a higher level of bias. However, it is comparable to other research trials completed in the real life PR setting.[32]

We did not complete an economic evaluation of the home-based and centre-based programmes. However, the cost of the home programme with the supply of the SPACE for COPD manual has been previously estimated to be £181. [33]

Future studies should address the acceptability of this approach for individuals who decline the offer of rehabilitation at any stage of their COPD care pathway due to unacceptability of formal supervise rehabilitation programmes. Overall we believe that this standardised home based programme, supported by SPACE for COPD does offer significant benefits to participants as an alternative for supervised PR that should be considered.

## Acknowledgements

The authors would like to acknowledge the pulmonary rehabilitation team at Glenfield Hospital, Leicester NHS trust who recruited participants. We are grateful to all participants for their involvement in this study. The University Hospitals of Leicester own the IP for the SPACE for COPD manual.

## **Declaration of interests**

SS was supported by the NIHR Collaboration for Leadership in Applied Health Research and Care East Midlands (CLAHRC EM) and *by the National Institute for Health Research Leicester Respiratory Biomedical Research Unit.* The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health.

#### REFEENCES

- 1. Bolton CE, Bevan-Smith E, Blakey JD, et al. British Thoracic Society Guideline on Pulmonary Rehabilitation in Adults'. *Thorax* 2013 68 Suppl 2, ii1-ii30
- Spruit MA, Singh SJ, Garvey C, et al. An Official American Thoracic Society/European Respiratory Society Statement: Key Concepts and Advances in Pulmonary Rehabilitation. *Am J Respir Crit Care Med* 2013;188(8):e13-e64.
- Maltais F, Bourbeau J, Shapiro S, et al. Effects of Home-Based Pulmonary Rehabilitation in Patients with Chronic Obstructive Pulmonary Disease: A Randomized Trial. Ann Intern Med 2008;149(12):869-878.
- Güell MR, de Lucas P, Gáldiz JB., et al. Home Vs Hospital-Based Pulmonary Rehabilitation for Patients with Chronic Obstructive Pulmonary Disease: A Spanish Multicenter Trial. Arch Bronconeumol 2008;44(10):512-518.
- Puente-Maestu L, Sánz ML, Sánz P, et al. Comparison of Effects of Supervised Versus Self-Monitored Training Programmes in Patients with Chronic Obstructive Pulmonary Disease. *Eur Respir J* 2000;15(3):517-525
- Holland AE, Mahal A, Hill CJ et al. Home-based rehabilitation for COPD using minimal resources: a randomized, controlled equivalence trial. *Thorax* Published Online First: [04/10/2016] doi:10.1136/thoraxjnl-2016-208514.
- Spruit MA, Singh SJ, Garvey C, et al. An Official American Thoracic Society/European Respiratory Society Statement: Key Concepts and Advances in Pulmonary Rehabilitation. *Am J Respir Crit Care Med* 2013;188(8), e13-e64

- Keating A, Lee AL, and Holland AE. Lack of Perceived Benefit and Inadequate Transport Influence Uptake and Completion of Pulmonary Rehabilitation in People with Chronic Obstructive Pulmonary Disease: A Qualitative Study'. *Journal of Physiotherapy* 2011;57 (3), 183-190 DOI: http://dx.doi.org/10.1016/S1836-9553(11)70040-6
- **9.** Spruit MA, Pitta F, Garvey C, et al. Differences in Content and Organisational Aspects of Pulmonary Rehabilitation Programmes. *Eur Respir J* 2014;43(5):1326-1337.
- **10.** Mitchell KE, Johnson-Warrington V, Apps LD, et al. A self-management programme for COPD: a randomised controlled trial. *Eur Respir J* 2014;44(6):1538-1547.
- Lewin B, Robertson IH, Cay EL, et al. Effects of Self-Help Post-Myocardial-Infarction Rehabilitation on Psychological Adjustment and use of Health Services. *Lancet* 1992; 339 (8800), 1036-1040
- 12. Williams JE, Singh SJ, Sewell L, et al. Development of a Self-Reported Chronic Respiratory Questionnaire (CRQ-SR)'. *Thorax* 2001;56 (12), 954-959
- 13. Sewell L, Singh SJ, Williams JEA, et al. How Long should Outpatient Pulmonary Rehabilitation be? A Randomised Controlled Trial of 4 Weeks Versus 7 Weeks. *Thorax* 2006;61(9):767-771
- 14. Apps LD, Mitchell KE, Harrison SL, et al. The Development and Pilot Testing of the Self-Management Programme of Activity, Coping and Education for Chronic Obstructive Pulmonary Disease (SPACE for COPD). *Int J Chron Obstruct Pulmon Dis* 2013;8:317-327.

- 15. Zigmond AS and Snaith RP. The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand 1983;67(6):361-370.
- 16. Vincent E, Sewell L, Wagg K, et al. Measuring a Change in Self-Efficacy Following Pulmonary Rehabilitation: An Evaluation of the PRAISE Tool. *Chest* 2011;140(6):1534-1539.
- 17. Singh SJ, Morgan MD, Scott S, et al. Development of a Shuttle Walking Test of
  Disability in Patients with Chronic Airways Obstruction. *Thorax* 1992;47 (12), 10191024
- 18. Revill SM, Morgan MD, Singh SJ, et al. The Endurance Shuttle Walk: A New Field Test for the Assessment of Endurance Capacity in Chronic Obstructive Pulmonary Disease. *Thorax* 1999;54 (3), 213-222
- **19.** Jaeschke R, Singer J, and Guyatt GH. Measurement of Health Status. Ascertaining the Minimal Clinically Important Difference. *Control Clin Trials* 1989;10(4):407-415.
- 20. Piaggio G, Elbourne DR, Pocock SJ, et al.; CONSORT Group. Reporting of Noninferiority and Equivalence Randomized Trials: Extension of the CONSORT 2010 Statement. JAMA 2012;308(24):2594-2604.
- 21. Singh SJ, Jones PW, Evans R, et al. Minimum Clinically Important Improvement for the Incremental Shuttle Walking Test. *Thorax* 2008;63(9):775-777.
- 22. Pepin V, Laviolette L, Brouillard C, et al. Significance of Changes in Endurance Shuttle Walking Performance. *Thorax* 2011;66(2):115-120.
- 23. Rubin DB. Multiple imputation for nonresponses in surveys. New York: John Wiley & Sons 1987.

- 24. Effing T, Zielhuis G, Kerstjens H, et al. Community Based Physiotherapeutic Exercise in COPD Self-Management: A Randomised Controlled Trial. *Respir Med* 2011;105(3):418-426.
- 25. Monninkhof E, van der Valk P, van der Palen J, et al. Effects of a Comprehensive Self-Management Programme in Patients with Chronic Obstructive Pulmonary Disease. *Eur Respir J* 2003;22(5):815-820.
- 26. Boxall A, Barclay L, Sayers A, et al. Managing Chronic Obstructive Pulmonary Disease in the Community. A Randomized Controlled Trial of Home-Based Pulmonary Rehabilitation for Elderly Housebound Patients. J Cardiopulm Rehabil 2005;25(6):378-385.
- 27. Chaplin E, Hewitt S, Apps L, et al. Interactive web-based pulmonary rehabilitation programme: a randomised controlled feasibility trial. BMJ Open 2017;7:e013682.
  doi:10.1136/bmjopen-2016-013682
- 28. Ninot G, Moullec G, Picot MC, et al. Cost-Saving Effect of Supervised Exercise Associated to COPD Self-Management Education Program. Respir Med 2011;105(3):377-385.
- **29.** Evans RA, Singh SJ, Collier R, et al. Pulmonary Rehabilitation is Successful for COPD Irrespective of MRC Dyspnoea Grade. *Respir Med* 2009;103(7):1070-1075.
- 30. Greening NJ, Evans RA, Williams JE, et al. Does Body Mass Index Influence the Outcomes of a Waking-Based Pulmonary Rehabilitation Programme in COPD? *Chron Respir Dis* 2012;9(2):99-106.
- 31. Sewell L, Singh SJ, Williams JEA, et al. Can Individualized Rehabilitation Improve
  Functional Independence in Elderly Patients with COPD? *Chest* 2005;128(3):11941200.

- 32. Boutou AK, Tanner RJ, Lord VM, et al. An evaluation of factors associated with completion and benefit from pulmonary rehabilitation in COPD. *BMJ Open Respir Res* 2014; 1:e000051. doi:10.1136/bmjresp-2014-000051
- 33. Dritsaki M, Johnson-Warrington V, Mitchell K et al. An economic evaluation of a selfmanagement programme of activity, coping and education for patients with chronic obstructive disease. *Chron Respir Dis* 2016:13 (1):48-56. Published Online First 23 December 2015 Doi 10.1177/1479972315619578